ALS patients get expanded access to experimental Sugar-Based drug
NCT ID NCT05597436
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This program gives ALS patients who cannot join other clinical trials access to an experimental drug called trehalose (SLS-005). Trehalose is a sugar solution given once a week through a vein. The goal is to see if it can help control the disease. The program is no longer available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trehalose (SLS-005)
- What this could lead to
- If this works, it could slow progression of ALS and improve quality of life for patients who cannot join other trials.
- What could go wrong
- This is an expanded access program, not a formal trial, so evidence is limited. Trehalose is still investigational and may not slow the disease or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
George Washington University
Washington D.C., District of Columbia, 20052, United States
-
Holy Cross Hospital - Phil Smith Neuroscience Institute
Fort Lauderdale, Florida, 33308, United States
-
Hospital for Special Care
New Britain, Connecticut, 06053, United States
-
Lehigh Valley Hospital
Allentown, Pennsylvania, 18105, United States
-
Nova Southeastern University
Fort Lauderdale, Florida, 33328, United States
-
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
-
Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706, United States
-
Sean M. Healey & AMG Center for ALS Neurological Clinical Research Institute, Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Spectrum Health/Corewell Health
Grand Rapids, Michigan, 49503, United States
-
Texas Neurology, P.A.-Neal Site:769
Dallas, Texas, 75206, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of California, Irvine
Orange, California, 92697, United States
-
University of California, San Francisco
San Francisco, California, 94115, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Maryland School of Medicine
Baltimore, Maryland, 21201, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
Virginia Commonwealth University Clinical Research Unit
Richmond, Virginia, 23298, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a brain disease change behavior years before diagnosis?
- Can a cancer drug slow ALS? a trial aims to find out
- Can conversation unlock clues to ALS speech decline?
- Could a simple Pre-Tube ritual ease feeding problems in ALS?
- Can tracking brain changes over time unlock the secrets of frontotemporal dementia?
- A muscle test in the thigh may reveal how ALS attacks the body